Abstract
Abstract Background Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and is one of the most common causes of chronic liver disease, worldwide. Lipoproteinassociated phospholipase A2 (Lp-PLA2) was recently characterized as a novel inflammatory biomarker that is correlated with several components constituting the metabolic syndrome. Aim and Objectives to study serum levels of Lp-PLA2 in patients with NAFLD to detect its relation to the incidence and severity of NAFLD. Subjects and Methods This is Case Control cross -sectional clinical Study, was carried out at Internal Medicine and Hepatology outpatient clinic at Ain Shams University Hospital on 80 persons were divided into 2 groups: (Group-I): 40 patient with NAFLD as a study group, (GroupII): Forty(40) healthy subjects as a control group. Result There was high statistically significant difference between the studied groups as regard LpPLA2. Conclusion The clinical use of Lp-PLA2, a biomarker for NAFLD, requires the standardization of analytical methods, characterization of analytical features, assessment of performance characteristics, incremental yield of different markers for given clinical indications, and demonstration of cost-effectiveness.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
